301 related articles for article (PubMed ID: 26577047)
1. Proposed therapies in primary biliary cholangitis.
Floreani A; Sun Y; Zou ZS; Li B; Cazzagon N; Bowlus CL; Gershwin ME
Expert Rev Gastroenterol Hepatol; 2016; 10(3):371-382. PubMed ID: 26577047
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
Yang Y; He X; Rojas M; Leung PSC; Gao L
Front Immunol; 2023; 14():1184252. PubMed ID: 37325634
[TBL] [Abstract][Full Text] [Related]
3. Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota-Bile Acid-Immunity Network.
Guo Z; He K; Pang K; Yang D; Lyu C; Xu H; Wu D
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673905
[TBL] [Abstract][Full Text] [Related]
4. Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.
Zhao Y; Wei S; Chen L; Zhou X; Ma X
Front Immunol; 2023; 14():1164202. PubMed ID: 37457696
[TBL] [Abstract][Full Text] [Related]
5. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches.
Galoosian A; Hanlon C; Zhang J; Holt EW; Yimam KK
J Clin Transl Hepatol; 2020 Mar; 8(1):49-60. PubMed ID: 32274345
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic role of oxidative and nitrosative stress in primary biliary cirrhosis.
Grattagliano I; Calamita G; Cocco T; Wang DQ; Portincasa P
World J Gastroenterol; 2014 May; 20(19):5746-59. PubMed ID: 24914336
[TBL] [Abstract][Full Text] [Related]
7. Elafibranor in primary biliary cholangitis.
Kotsiliti E
Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):2. PubMed ID: 38036746
[No Abstract] [Full Text] [Related]
8. Immunobiology of the biliary tract system.
Björkström NK
J Hepatol; 2022 Dec; 77(6):1657-1669. PubMed ID: 36116989
[TBL] [Abstract][Full Text] [Related]
9. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis-Authors' reply.
Burghart L; Hofer BS; Halilbasic E; Simbrunner B; Staettermayer AF; Trauner M; Reiberger T
Aliment Pharmacol Ther; 2024 Jul; 60(1):107-108. PubMed ID: 38803242
[No Abstract] [Full Text] [Related]
10. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.
Ao X; Zeng Y; Wang X; Fan X
Aliment Pharmacol Ther; 2024 Jul; 60(1):105-106. PubMed ID: 38803269
[No Abstract] [Full Text] [Related]
11. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés A
Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the diagnosis and treatment of primary biliary cholangitis.
Huang YQ
World J Hepatol; 2016 Nov; 8(33):1419-1441. PubMed ID: 27957241
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for the treatment of Primary Biliary Cholangitis.
Ali AH; Tabibian JH; Carey EJ; Lindor KD
Expert Opin Emerg Drugs; 2016; 21(1):39-56. PubMed ID: 26901615
[TBL] [Abstract][Full Text] [Related]
15. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.
Bowlus CL
Hepat Med; 2016; 8():89-95. PubMed ID: 27621676
[TBL] [Abstract][Full Text] [Related]
16. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
18. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
19. Making Sense of Autoantibodies in Cholestatic Liver Diseases.
Marzorati S; Invernizzi P; Lleo A
Clin Liver Dis; 2016 Feb; 20(1):33-46. PubMed ID: 26593289
[TBL] [Abstract][Full Text] [Related]
20. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
